THE TGA has approved the first
biologic therapy for children and
adolescents (6-17 years of age)
with ulcerative colitis who have had
an inadequate response to
conventional therapy, Remicade
(infliximab).
The drug approval follows a study
which found that the drug induced
a clinical response after eight
weeks in 73.3% of paediatric
patients with moderately severe to
severe active ulcerative colitis who
did not respond to corticosteroids
or other conventional therapies.The above article was sent to subscribers in Pharmacy Daily's issue from 04 Oct 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Oct 12
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.